You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

New Horizons in Neovascular Age-Related Macular Degeneration: Latest Data and Expert Thoughts on Emerging Therapies

  • Authors: Karl G. Csaky, MD, PhD; Carl Danzig, MD; Carl D. Regillo, MD; SriniVas R. Sadda, MD
  • CME Released: 3/29/2021
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 3/29/2022
Start Activity


Target Audience and Goal Statement

This activity is intended for ophthalmologists.

This activity will increase knowledge about emerging therapies for neovascular age-related macular degeneration (nAMD), including the latest research findings and their placement in different patient populations with retinal diseases.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Advantages of emerging therapies in nAMD
    • Latest clinical data for nAMD
  • Have greater competence related to
    • Evaluating emerging therapies for different patient populations with retinal diseases


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.


Faculty

  • Karl G. Csaky, MD, PhD

    T. Boone Pickens Senior Scientist
    Chief Executive and Chief Medical Officer
    Retina Foundation of the Southwest
    Dallas, Texas

    Disclosures

    Disclosure: Karl G. Csaky, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Acucela; Allergan; Astellas; Cognition Therapeutics; Heidelberg Engineering; Johnson & Johnson; NGM Biopharmaceuticals; Ocular Therapeutix; Ophthotech; Retrotope; Ribomics; Roche/Genentech
    Received grants for clinical research from: Gyroscope; Ionis; IVERIC Bio; NGM Biopharmaceuticals; Roche/Genentech

  • Carl Danzig, MD

    Affiliate Assistant Professor of Clinical Biomedical Science
    Charles E. Schmidt College of Medicine
    Florida Atlantic University
    Boca Raton, Florida
    Director of Vitreo-Retinal Services
    Rand Eye Institute
    Pompano Beach, Florida

    Disclosures

    Disclosure: Carl Danzig, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Genentech; Novartis; Regeneron
    Served as a speaker or a member of a speakers bureau for: Novartis
    Received grants for clinical research from: Adverum; Genentech; Novartis; Roche

  • Carl D. Regillo, MD

    Director, Retina Service
    Wills Eye Hospital
    Professor of Ophthalmology
    Thomas Jefferson University
    Philadelphia, Pennsylvania

    Disclosures

    Disclosure: Carl D. Regillo, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Adverum; Allergan; Annexon; Chengdu Kanghong; Genentech; Graybug; Iveric; Kodiak; Lineage; Merck; NGM Biopharmaceuticals; Notal; Novartis; Stealth; Takeda; Thea
    Received grants for clinical research from: Adverum; Allergan; Annexon; Chengdu Kanghong; Genentech; Graybug; Iveric; Lineage; NGM; Novartis; Opthea; Regeneron; Regenexbio

  • SriniVas R. Sadda, MD

    Professor of Ophthalmology
    University of California, Los Angeles
    President and Chief Scientific Officer
    Stephen J. Ryan-Arnold and Mabel Beckman Foundation Endowed Presidential Chair
    Doheny Eye Institute
    Los Angeles, California

    Disclosures

    Disclosure: SriniVas R. Sadda, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Allergan; Amgen; Apellis; Bayer; Centervue; Heidelberg; Merck; Novartis; Optos; Oxurion; Regeneron; Roche/Genentech
    Served as a speaker or a member of a speakers bureau for: Carl Zeiss Meditec; Nidek; Novartis
    Received grants for clinical research from: Carl Zeiss Meditec
    Other: Research Instruments: Nidek, Topcon, Heidelberg, Carl Zeiss Meditec, Centervue, Optos

Editors

  • Pakinam Aboulsaoud, PharmD

    Medical Education Director, Medscape, LLC 

    Disclosures

    Disclosure: Pakinam Aboulsaoud, PharmD, has disclosed no relevant financial relationships.  

  • Yoji Yamaguchi, MA, ELS

    Associate Scientific Content Manager, Medscape, LLC 

    Disclosures

    Disclosure: Yoji Yamaguchi, MA, ELS, has disclosed no relevant financial relationships. 

CME Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

The PIM planners and others have nothing to disclose.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alimera; Allergan; Carl Zeiss Meditec; Thea


Accreditation Statements

Developed through a partnership between Medscape and Postgraduate Institute for Medicine (PIM)



In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Medscape, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Postgraduate Institute for Medicine is accredited by COPE to provide continuing education to optometrists.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50  AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    For Optometrists



    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Medscape. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Postgraduate Institute for Medicine is accredited by COPE to provide continuing education to optometrists.

    This course is COPE approved for 0.75 hours of CE credit. Activity # 121441 and Course ID 71970-PS  Check with your local state licensing board to see if this counts toward your CE requirement for re-licensure.

    Reviewed by 

    Contact this provider www.pimed.com

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

New Horizons in Neovascular Age-Related Macular Degeneration: Latest Data and Expert Thoughts on Emerging Therapies

Authors: Karl G. Csaky, MD, PhD; Carl Danzig, MD; Carl D. Regillo, MD; SriniVas R. Sadda, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 3/29/2021

Valid for credit through: 3/29/2022

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

New Pathways and Technologies in Treating Neovascular Age-Related Macular Degeneration


Karl G. Csaky, MD, PhD

Latest Data in nAMD From the Angiogenesis, Exudation, and Degeneration 2021 Meeting


Carl Danzig, MD

Emerging Treatments in Neovascular Age-Related Macular Degeneration: What Change Will They Bring?


Carl D. Regillo, MD; SriniVas R. Sadda, MD
 

Educational Impact Challenge

This activity will increase knowledge about emerging therapies for neovascular age-related macular degeneration (nAMD), including the latest research findings and their placement in different patient populations with retinal diseases.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print